| 0.98 0.02 (2.12%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.24 | 1-year : | 1.36 |
| Resists | First : | 1.06 | Second : | 1.16 |
| Pivot price | 1.01  |
|||
| Supports | First : | 0.89 | Second : | 0.74 |
| MAs | MA(5) : | 0.98 |
MA(20) : | 1 |
| MA(100) : | 0.77 |
MA(250) : | 1.31 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.8 |
D(3) : | 28.8 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 3.11 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MTVA ] has closed above bottom band by 28.3%. Bollinger Bands are 32.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.98 - 0.99 | 0.99 - 0.99 |
| Low: | 0.96 - 0.96 | 0.96 - 0.97 |
| Close: | 0.97 - 0.98 | 0.98 - 0.99 |
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Mon, 20 Oct 2025
MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025 - PR Newswire
Tue, 14 Oct 2025
MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference - Stock Titan
Wed, 17 Sep 2025
We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate - simplywall.st
Wed, 17 Sep 2025
We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate - Yahoo Finance
Tue, 26 Aug 2025
Novel Dual GLP1R/GCGR Obesity Drug: MetaVia to Showcase DA-1726 at Major Healthcare Conferences - Stock Titan
Wed, 13 Aug 2025
MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025… - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 62.5 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 108 (K) |
| Shares Short P.Month | 122 (K) |
| EPS | -0.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -53.1 % |
| Return on Equity (ttm) | -129.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -1.02 |
| PEG Ratio | 0 |
| Price to Book value | 2.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|